Syringetin

Syringetin

SCHEMBL810981

COc1cc(-c2oc3cc(O)cc(O)c3c(=O)c2O)cc(OC)c1O

nearest known ligand 0.85

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 7/20 0.85
CYP1A2 P05177 8/20 0.79
MEN1 O00255 8/20 0.79
KMT2A Q03164 8/20 0.79
CYP1A1 P04798 7/20 0.79
CYP1B1 Q16678 7/20 0.79
XDH P47989 6/20 0.79
IPMK Q8NFU5 4/20 0.79
IP6K2 Q9UHH9 4/20 0.79
CA12 O43570 4/20 0.79
PPARG P37231 4/20 0.79
CA7 P43166 4/20 0.79
CA2 P00918 3/20 0.79
CA4 P22748 3/20 0.79
MAOA P21397 6/20 0.70
FTO Q9C0B1 5/20 0.70
CYP3A4 P08684 5/20 0.70
CYP2C9 P11712 5/20 0.70
AKR1B1 P15121 4/20 0.70
BCHE P06276 4/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Syringetin SCHEMBL29929167 1.00 ABCB1 (0.85) ABCB1CYP1A2MEN1KMT2ACYP1A1
Laricytrin SCHEMBL29929477 0.96 ABCB1 (0.83) ABCB1CYP1A2MEN1KMT2ACYP1A1
Laricytrin SCHEMBL19213534 0.96 ABCB1 (0.83) ABCB1CYP1A2MEN1KMT2ACYP1A1
SCHEMBL19249162 0.92 ABCB1 (0.78) ABCB1CYP1A2MEN1KMT2ACYP1A1
SCHEMBL4034698 0.92 ABCB1 (1.00) ABCB1CYP1A2MEN1KMT2ACYP1A1
SCHEMBL30255771 0.92 ABCB1 (1.00) ABCB1CYP1A2MEN1KMT2ACYP1A1
SCHEMBL3452793 0.90 ABCB1 (0.77) ABCB1CYP1A2MEN1KMT2ACYP1A1
SCHEMBL4649105 0.90 ABCB1 (0.70) ABCB1CYP1A2MEN1KMT2ACYP1A1
Isorhamnetin SCHEMBL19235 0.88 MEN1 (1.00) ABCB1CYP1A2MEN1KMT2ACYP1A1
SCHEMBL7375699 0.88 ABCB1 (0.68) ABCB1CYP1A2MEN1KMT2ACYP1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240315965-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2024-09-26 US claimed
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2023-03-23 US claimed
WO-2023004029-A1 COMPOSITION FOR PREVENTING TEETH STAINING ONSTAD ANDREW (US) 2023-01-26 WO claimed
WO-2022182527-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2022-09-01 WO claimed
WO-2022182523-A1 COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2022-09-01 WO claimed
WO-2021158575-A1 COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO claimed
WO-2021158573-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO claimed
WO-2020136240-A1 POLYPHENOL-PEPTIDE CONJUGATES FOR NUCLEAR-TARGETED DELIVERY Universität Wien (AT) 2020-07-02 WO claimed
EP-3673920-A1 POLYPHENOL-PEPTIDE CONJUGATES FOR NUCLEAR-TARGETED DELIVERY Universität Wien (AT) 2020-07-01 EP claimed
CN-106389406-B A kind of application of blood sugar reducing function compound 中国药科大学 2019-02-22 CN claimed
CN-107773557-A The medicinal usage of syringetin 上海华堇生物技术有限责任公司 2018-03-09 CN claimed
CN-106389406-A Applications of blood glucose lowering compound 中国药科大学 2017-02-15 CN claimed
US-20120208118-A1 RESIN COMPOSITIONS AND PROCESSES XEROX CORPORATION (US) 2012-08-16 US claimed
US-6872771-B1 Tire with rubber containing flavone THE GOODYEAR TIRE & RUBBER COMPANY (US) 2005-03-29 US claimed
JP-2003504327-A 2003-02-04 JP claimed
EP-1223928-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS Prendergast, Patrick Thomas (IE) 2002-07-24 EP claimed
WO-2001003681-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS PRENDERGAST PATRICK T (IE) 2001-01-18 WO claimed
US-20260090573-A1 REDUCED-SUGAR FRUIT JUICE AND FRUIT MUST INNOVATIVE STRATEGIC DESIGN, LLC (US) 2026-04-02 US disclosed
EP-1223928-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS Prendergast, Patrick Thomas (IE) 2002-07-24 EP disclosed
WO-2001003681-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS PRENDERGAST PATRICK T (IE) 2001-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES FABP2, FABP4, GUSB ABCB1 719/4885CYP1A2 3865/4885MEN1 1711/4885
US-20260090573-A1 REDUCED-SUGAR FRUIT JUICE AND FRUIT MUST KCNN2, KCNN1, PROC ABCB1 3785/4885CYP1A2 4521/4885MEN1 946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.